JP7849074B2 - 標的化剤 - Google Patents

標的化剤

Info

Publication number
JP7849074B2
JP7849074B2 JP2024517316A JP2024517316A JP7849074B2 JP 7849074 B2 JP7849074 B2 JP 7849074B2 JP 2024517316 A JP2024517316 A JP 2024517316A JP 2024517316 A JP2024517316 A JP 2024517316A JP 7849074 B2 JP7849074 B2 JP 7849074B2
Authority
JP
Japan
Prior art keywords
antibody
domain
seq
amino acid
motor neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024517316A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023210585A1 (https=
Inventor
法弘 湯本
大二郎 猪俣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiksak Bioengineering Inc
Original Assignee
Jiksak Bioengineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiksak Bioengineering Inc filed Critical Jiksak Bioengineering Inc
Publication of JPWO2023210585A1 publication Critical patent/JPWO2023210585A1/ja
Application granted granted Critical
Publication of JP7849074B2 publication Critical patent/JP7849074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024517316A 2022-04-25 2023-04-24 標的化剤 Active JP7849074B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022071453 2022-04-25
JP2022071453 2022-04-25
PCT/JP2023/016125 WO2023210585A1 (ja) 2022-04-25 2023-04-24 標的化剤

Publications (2)

Publication Number Publication Date
JPWO2023210585A1 JPWO2023210585A1 (https=) 2023-11-02
JP7849074B2 true JP7849074B2 (ja) 2026-04-21

Family

ID=88518850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517316A Active JP7849074B2 (ja) 2022-04-25 2023-04-24 標的化剤

Country Status (5)

Country Link
US (1) US20250277028A1 (https=)
EP (1) EP4516316A4 (https=)
JP (1) JP7849074B2 (https=)
AU (1) AU2023259903A1 (https=)
WO (1) WO2023210585A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024281601A1 (en) 2023-05-31 2026-01-08 Jiksak Bioengineering, Inc. Anti-synaptotagmin 2 antibody
JPWO2024248063A1 (https=) 2023-05-31 2024-12-05
WO2025084395A1 (ja) * 2023-10-19 2025-04-24 株式会社Jiksak Bioengineering 抗シナプトタグミン２抗体
WO2025084396A1 (ja) * 2023-10-19 2025-04-24 株式会社Jiksak Bioengineering 抗シナプトタグミン２抗体
WO2025089344A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089346A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体
WO2025089342A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089347A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体
WO2025089345A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトジャイリン３抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506358A (ja) 2004-03-29 2008-03-06 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン シナプトフィジンに対する特異的結合要素
JP2012501646A (ja) 2008-09-04 2012-01-26 ガレニア コーポレーション シナプス小胞サイクリングアッセイおよびシステム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
WO2005016233A2 (en) * 2002-10-31 2005-02-24 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
DE102005051789B4 (de) * 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
JP2008143867A (ja) 2006-12-12 2008-06-26 Institute Of Physical & Chemical Research シナプス形成促進剤
JP2012092048A (ja) 2010-10-27 2012-05-17 Keio Gijuku 軽度認知障害の治療用医薬剤、初期認知症の治療用医薬剤、神経細胞の樹状突起形成促進剤、神経細胞のシナプス形成促進剤、検定方法およびスクリーニング方法
JP7323874B2 (ja) 2019-03-27 2023-08-09 国立大学法人東北大学 神経軸索分岐異常の改善剤
JP7849713B2 (ja) 2019-07-05 2026-04-22 株式会社Jiksak Bioengineering 神経細胞のシナプス形成誘導方法および該方法に用いるマイクロビーズ
JP2022053535A (ja) 2020-09-24 2022-04-05 株式会社Jiksak Bioengineering シナプス形成を促進するための組成物
JP2022071453A (ja) 2020-10-28 2022-05-16 セイコーエプソン株式会社 殺菌装置
JP2023028848A (ja) 2021-08-20 2023-03-03 株式会社Jiksak Bioengineering シナプス形成促進剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506358A (ja) 2004-03-29 2008-03-06 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン シナプトフィジンに対する特異的結合要素
JP2012501646A (ja) 2008-09-04 2012-01-26 ガレニア コーポレーション シナプス小胞サイクリングアッセイおよびシステム

Also Published As

Publication number Publication date
JPWO2023210585A1 (https=) 2023-11-02
AU2023259903A1 (en) 2024-11-21
EP4516316A1 (en) 2025-03-05
EP4516316A4 (en) 2026-04-22
WO2023210585A1 (ja) 2023-11-02
US20250277028A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
JP7849074B2 (ja) 標的化剤
Zapata et al. Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission
Zhang et al. TMEM25 modulates neuronal excitability and NMDA receptor subunit NR2B degradation
EP3995509A1 (en) Method for inducing neuronal synapse formation and microbeads used in said method
Vandestadt et al. Early migration of precursor neurons initiates cellular and functional regeneration after spinal cord injury in zebrafish
CA3257052A1 (en) Targeting agent
US20240103015A1 (en) Methods for assaying slc34a2 expression in muscle tissue and treating facioscapulohumeral muscular dystrophy
US20240173356A1 (en) Extracellular Vesicles From Human Induced Pluroptent Stem Cells
WO2025089345A1 (ja) 抗シナプトジャイリン３抗体
WO2025089342A1 (ja) 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089344A1 (ja) 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089346A1 (ja) 抗シナプトフィジン抗体
WO2025084395A1 (ja) 抗シナプトタグミン２抗体
WO2025084397A1 (ja) 抗シナプトタグミン２抗体
WO2025084393A1 (ja) 抗シナプトタグミン２抗体
Li et al. Peripheral gating of pain by glial endozepine
WO2025084396A1 (ja) 抗シナプトタグミン２抗体
WO2025084394A1 (ja) 抗シナプトタグミン２抗体
WO2025089341A1 (ja) 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089343A1 (ja) 抗シナプス小胞糖タンパク質２ｃ抗体
WO2024248062A1 (ja) 抗シナプトタグミン２抗体
WO2024248063A1 (ja) 抗シナプトタグミン２抗体
WO2025089349A1 (ja) 抗シナプトフィジン抗体
WO2025089348A1 (ja) 抗シナプトフィジン抗体
WO2025089347A1 (ja) 抗シナプトフィジン抗体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7849074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150